Important Note: Redirection of Services to ChiCTR
We would like to inform you that the Clinical Trial Registry page will discontinue the function of updating trial information directly on this platform. However, you will still be able to view the existing registration details. For any updates to trial information, you can use the China Clinical Trial Registry (ChiCTR) directly at https://www.chictr.org.cn. This change will be fully implemented by 2024-Aug-05. Thank you for your attention.
CUHK_CCT00042
2005-09-08
Retrospective
Not applicable
RGC grant and Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong
Nil
Nil
Miss Joyce Kung
3/F, Hong Kong Eye Hospital, 147K Argyle Street, Kowloon
27623134
joycekung@cuhk.edu.hk
Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong
Dr. Timothy Y.Y. Lai
3/F, Hong Kong Eye Hospital, 147K Argyle Street, Kowloon.
27623134
eyeclinic@cuhk.edu.hk
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong
A Randomized, Controlled Trial of Photodynamic Therapy with Verteporfin for Choroidal Neovascularization in Pathologic Myopia in Chinese
A Randomized, Controlled Trial of Photodynamic Therapy with Verteporfin for Choroidal Neovascularization in Pathologic Myopia in Chinese
Nil
Hong Kong
Yes
2002-04-01
Eye Diseases
Procedure
Photodynamic therapy
24 months
observation
Inclusion criteria: aged 18 years or older
CNV either in the subfoveal or juxtafoveal area Area of CNV >/= 50% of the area of the total lesion Greatest linear dimension of the entire lesion must not exceed 5400 µm Best-corrected visual acuity score of at least 34 letters (Snellen equivalent, approximately 20/200 or better) Understand the study and sign the informed consent
Exclusion criteria: Other clinical features suggesting that the CNV may be secondary to the other causes other than pathologic myopia (such as large drusen, geographical atrophy, choroioretinal scar) Tear (rip) of the retinal pigment epithelium Any other significant concurrent ocular diseases in study eye disease that has compromised or could compromise vision in the study eye History of the other prior forms of treatment including photodynamic therapy, laser, surgery Active hepatitis or clinically significant liver disease Porphyria or hypersensitivity/allergy to treatment (fluorescein, verteporfin) Pregnancy
18
None set
Both Male and Female
Interventional
Randomized
Placebo
Single-blind
Single group
2003-01-01
72
Complete
Visual acuity
changes in cnv by angiography and optical coherent tomography
2013-01-14
ChiCTR-TRC-05000641
2010-05-04
|
|
|
|
---|---|---|---|
No documents yet. |